Agios lines up another potential FDA nod with new leukemia drug

Less than five months after getting its first cancer drug approved, Cambridge-based Agios Pharmaceuticals has lined up another potential FDA nod — and the first for a medicine that it fully owns. Agios (Nasdaq: AGIO) said Tuesday that it had submitted an application for ivosidenib, a potential drug for patients with acute myeloid leukemia who have a specific genetic mutation, and whose cancer has relapsed or isn’t responding to initial treatment. The company said it had asked the FDA to review…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news